Multi-omics “upstream analysis” of regulatory genomic regions helps identifying targets against methotrexate resistance of colon cancer

详细信息    查看全文

• 作者：Alexander E. Kel^a ; ^b ; ^c ; ^{alexander.kel@genexplain.com} ; ^{alexander.kel2@googlemail.com} ; Philip Stegmaier^c ; Tagir Valeev^b ; ^d ; Jeannette Koschmann^c ; Vladimir Poroikov^e ; Olga V. Kel-Margoulis^c ; Edgar Wingender^c ; ^f
• 关键词：Proteomics data ; Microarray data ; ChIP-seq ; Upstream analysis ; Promoter analysis ; Pathway analysis
• 刊名：EuPA Open Proteomics
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：13
• 期：Complete
• 页码：1-13
• 全文大小：2789 K
• 卷排序：13

文摘

Upstream analysis strategy for multi-omics data is proposed. Drug targets are predicted by search for TFBS and analysis of signaling network. Methotrexate resistance data include transcriptomics, proteomics and epigenomics. Predicted targets are: TGFalpha, IGFBP7, alpha9-integrin. Predicted drugs are: zardaverine, divalproex and human metabolite nicotinamide N-oxide.